Photo of Michele K. Mass, M.D.

Michele K. Mass M.D.

Dr. Mass specializes in multiple sclerosis and neuropathology. She received her medical degree in 1983 from OHSU, which is where she also completed her residency training in neurology. Dr. Mass completed her neuropathology fellowship at the University of Washington in Seattle. She is board certified in neurology and neuropathology. 

  • Residency:

    • Neurology-Oregon Health & Science University, Portland
  • Fellowship:

    • Neuropathology-University of Washington, Seattle

Memberships and associations

  • Neurology, 1992

Publications

  • "The contemporary spectrum of multiple sclerosis misdiagnosis." Neurology In: , Vol. 87, No. 13, 27.09.2016, p. 1393-1399.
  • "Evaluation of dalfampridine extended release 5 and 10 mg in multiple sclerosis : A randomized controlled trial." International Journal of MS Care In: , Vol. 17, No. 3, 2015, p. 138-145.
  • "Microbial DNA testing for inflammatory diseases of the brain of uncertain etiology." Neurology: Clinical Practice  In: , Vol. 4, No. 3, 2014, p. 192-198.
  • "Randomized controlled trial of atorvastatin in clinically isolated syndrome : The STAyCIS study." Neurology In: , Vol. 78, No. 15, 10.04.2012, p. 1171-1178.
  • "Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis." Immunology In: , Vol. 123, No. 1, 01.2008, p. 66-78.
  • "Drought, vegetation change, and human history on Rapa Nui (Isla de Pascua, Easter Island)." Quaternary Research  In: , Vol. 69, No. 1, 01.2008, p. 16-28.
  • "Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients." Multiple Sclerosis In: , Vol. 11, No. 6, 12.2005, p. 626-634.
  • "A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis." Multiple Sclerosis In: , Vol. 11, No. 5, 10.2005, p. 552-561.
  • "Eight-year immunogenicity and safety of interferon beta-1a-Avonex® treatment in patients with multiple sclerosis." Multiple Sclerosis  In: , Vol. 11, No. 4, 08.2005, p. 409-419.
  • "Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis." Neurology In: , Vol. 64, No. 6, 22.03.2005, p. 992-995.
  • "Randomized controlled trial of yoga and exercise in multiple sclerosis." Neurology In: , Vol. 62, No. 11, 08.06.2004, p. 2058-2064.
  • "Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis." Multiple Sclerosis  In: , Vol. 9, No. 1, 02.2003, p. 1-5.
  • "Eight-year follow-up study of brain atrophy in patients with MS." Neurology In: , Vol. 59, No. 9, 12.11.2002, p. 1412-1420.
  • "Predictors of short-term disease activity following a first clinical demyelinating event : Analysis of the CHAMPS placebo group." Multiple Sclerosis In: , Vol. 8, No. 5, 2002, p. 405-409.
  • "Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis." Neurology In: , Vol. 57, No. 12 SUPPL. 5, 26.12.2001.
  • "Diminished frequency of interleukin-10-secreting, T-cell receptor peptide-reactive T cells in multiple sclerosis patients might allow expansion of activated memory T cells bearing the cognate BV gene." Journal of Neuroscience Research  In: , Vol. 66, No. 2, 15.10.2001, p. 171-176.
  • "Use of the multiple sclerosis functional composite to predict disability in relapsing MS." Neurology In: , Vol. 56, No. 10, 22.05.2001, p. 1324-1330.
  • "Relationship between brain atrophy and disability : An 8-year follow-up study of multiple sclerosis patients." Multiple Sclerosis In: , Vol. 6, No. 6, 2000, p. 373-377.
  • "Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis." Journal of Neuroimmunology In: , Vol. 93, No. 1-2, 01.01.1999, p. 8-14.
  • "Myelin basic protein-specific T lymphocytes induce chronic relapsing experimental autoimmune encephalomyelitis in lymphocyte-deficient (SCID) mice." Journal of Neuroimmunology In: , Vol. 93, No. 1-2, 01.01.1999, p. 92-101.
  • "Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis." Neurology In: , Vol. 50, No. 5, 05.1998, p. 1266-1272.
  • "Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis." Annals of Neurology In: , Vol. 43, No. 1, 01.1998, p. 79-87.
  • "Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials." Multiple Sclerosis In: , Vol. 4, No. 6, 1998, p. 480-486.
  • "Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis." Neurology In: , Vol. 49, No. 2, 08.1997, p. 358-363.
  • "Long-term toxicity and neuropathology associated with the sequencing of cranial irradiation and enhanced chemotherapy delivery." Neurosurgery In: , Vol. 40, No. 5, 05.1997, p. 1034-1042.
  • "Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis." Archives of Neurology In: , Vol. 54, No. 6, 1997, p. 731-736.
  • "Treatment of multiple sclerosis with T-cell receptor peptides : Results of a double-blind pilot trial." Nature Medicine In: , Vol. 2, No. 10, 10.1996, p. 1109-1115.
  • "Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis." Annals of Neurology In: , Vol. 39, No. 3, 1996, p. 285-294.
  • "Treatment of relapsing autoimmune encephalomyelitis with T cell receptor Vβ-specific antibodies when proteolipid protein is the autoantigen." Journal of Neuroscience Research In: , Vol. 45, No. 2, 1996, p. 104-116.
  • "Encephalitogenic T lymphocytes develop from SJL/J hematopoietic cells transplanted into severe combined immimodeficient ( SCID) mice." Journal of Neuroimmunology In: , Vol. 57, No. 1-2, 1995, p. 155-164.

Additional information

Edit profile